Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROMOCRIPTINE MESYLATE vs KYNMOBI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
Treatment of hypomobility, off episodes, and end-of-dose wearing-off in patients with advanced Parkinson disease,Off-label: Treatment of erectile dysfunction
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Extensively metabolized in the liver by glucuronidation via UGT1A1 and UGT2B7; also undergoes sulfation. N-demethylation via CYP1A2 and CYP3A4 may occur. No active metabolites identified.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
Apomorphine is approximately 90% bound to plasma proteins, primarily albumin.
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
The volume of distribution is approximately 200 L (about 2.9 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
Bioavailability of apomorphine is low and variable after oral administration (<5%). Subcutaneous administration provides 100% bioavailability. Sublingual film (KYNMOBI) has a bioavailability of approximately 18% relative to subcutaneous injection.
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
No specific dose adjustment provided; use caution in severe renal impairment (Cr Cl <30 m L/min) as data limited.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
No specific dose adjustment provided; use caution in Child-Pugh Class C as data limited.
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Safety and effectiveness in pediatric patients have not been established.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
No specific geriatric dose adjustment; pharmacokinetics similar to younger adults; monitor for hypotension and hallucinations.
None
KYNMOBI can cause serious adverse reactions, including severe nausea and vomiting, symptomatic orthostatic hypotension (particularly with concomitant antihypertensives), syncope, QT prolongation, and hallucinations/psychosis. It should not be used with serotonergic drugs due to risk of serotonin syndrome.
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Orthostatic hypotension/syncope; nausea/vomiting (pretreat with antiemetic); hallucinations/psychosis; impulse control disorders; dyskinesias; coronary and cerebral ischemia; QT prolongation; priapism; somnolence/sudden sleep onset; falls; cardiac valvulopathy (due to ergot-like activity); potential for abuse (dopaminergic dysregulation syndrome).
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, triptans) due to risk of serotonin syndrome; severe hepatic impairment; history of QT prolongation or concomitant QT-prolonging drugs; hypersensitivity to apomorphine or its components; use of 5-HT3 antagonists (e.g., ondansetron) for antiemesis (risk of profound hypotension).
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
No specific food interactions are reported; however, administer on an empty stomach or at least 30 minutes before or after meals to optimize absorption. Avoid grapefruit juice as it may increase apomorphine levels. Alcohol should be avoided due to additive sedative and hypotensive effects.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times the maximum human dose, respectively, on a mg/m² basis). No fetal malformations were observed. However, embryolethality and decreased fetal body weight occurred at maternally toxic doses in rabbits. Use during pregnancy only if potential benefit justifies potential risk to the fetus; first trimester risks are unknown.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
It is not known whether apomorphine is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
Pharmacokinetic changes during pregnancy may alter apomorphine clearance, although specific data are lacking. No dosing adjustment studies have been conducted. Use caution and monitor clinical response; dose adjustment may be necessary based on efficacy and tolerability, but no standard recommendation exists.
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
KYNMOBI (apomorphine sublingual film) is a rapid-onset, non-ergoline dopamine agonist for acute, intermittent treatment of OFF episodes in Parkinson disease. Onset of action occurs within 15-30 minutes. Administer film under the tongue and allow to dissolve completely; do not swallow saliva until dissolved. Nausea and vomiting are common pre-treatment with an antiemetic (e.g., trimethobenzamide) for at least 2 days prior. Monitor for hypotension, syncope, and QT prolongation. Avoid use with 5-HT3 antagonists (e.g., ondansetron) due to risk of profound hypotension. Do not use with apomorphine injection as it may lead to cumulative adverse effects.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
Place the film under your tongue and let it dissolve completely. Do not chew, swallow, or move the film with your tongue.,Do not eat or drink until the film has fully dissolved to ensure proper absorption.,Take KYNMOBI only at the first sign of an OFF episode to improve mobility.,You may experience nausea and vomiting; your doctor may prescribe an antiemetic to take before your first dose.,Avoid alcohol, as it may increase sedation and hypotension.,Do not drive or operate machinery until you know how KYNMOBI affects you, as it may cause dizziness, drowsiness, or sudden sleep onset.,Report any unusual urges (gambling, sexual, spending) to your doctor as these can occur with dopamine agonists.,Do not use this medicine more than 5 times per day or more often than every 2 hours.
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROMOCRIPTINE MESYLATE vs KYNMOBI, answered by our medical review team.
BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. KYNMOBI is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROMOCRIPTINE MESYLATE and KYNMOBI depend on the specific clinical indication. These are both Dopamine Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. The standard adult dose of KYNMOBI is: Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROMOCRIPTINE MESYLATE and KYNMOBI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. KYNMOBI is classified as Category C. Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.